[Psoriatic arthritis : Drugs of the (near) future].

The treatment of psoriatic arthritis (PsA) necessitates different and highly effective treatment strategies due to the diverse clinical manifestations. Drugs that exhibit efficacy for most of the musculoskeletal (e.g. arthritis, dactylitis, enthesitis and spondyloarthritis) and extra-articular manifestations (e.g. skin and nail lesions) are therefore of special interest. This review presents a selection of drugs for the treatment of PsA, which might be available within the (near) future. Based on an improved understanding of the pathopysiology of psoriasis as well as PsA, novel therapeutic approaches are under development. Results have already been obtained from phase 3 studies for tofacitinib, a Janus kinase inhibitor as well as for the antibodies brodalumab, bimekizumab and ABT-122 that inhibit the IL17-signaling pathway. The sphingolipid agonist ponesimod and the A3AR agonist CF101 represent "small molecules" similar to the Janus kinase inhibitors that will potentially extend the therapeutic options in the future.